Abstract:Abstract High-risk neuroblastoma is one of the most difficult to treat pediatric cancers, with a survival rate of only about 50% and significant long-term consequences from current chemotherapy. Preclinical models such as cell lines and mice are the backbone of drug development and experimental-mechanistic oncology, but the development of new treatments is hampered in part by a lack of understanding of the direct clinical relevance of such data collected in preclinical models. Despite this, few formal methods have been developed to determine how these various models represent/resemble primary patient tumors. Here, we present the first comprehensive single-cell RNA-seq analysis of neuroblastoma across an extensive cohort of patient tumors and a variety of preclinical model systems (n = 126 total samples assembled - the largest cohort of its kind). By building an innovative unsupervised machine learning method, which we term “automatic consensus nonnegative matrix factorization” (acNMF), we have integrated and contrasted the transcriptional landscapes of patient tumors with those of cell lines, patient-derived xenografts (PDX), and genetic mouse models (GEMM).Using these tools, we discovered the dominant adrenergic gene expression programs found in neuroblastoma patient tumors were preserved across all preclinical models. However, the presumptive chemo-resistant mesenchymal-like programs, while identifiable in cell lines, were primarily restricted to subpopulations of cancer-associated fibroblasts and Schwann-like cells in vivo. Surprisingly, a mesenchymal-like program could be acutely chemotherapy-induced in GEMM and was evident in pre-treated patient and PDX samples, suggesting a previously uncharacterized mechanism of therapy escape. In addition to these core findings, our computational tools were able to further delineate the classical neuroblastoma adrenergic and mesenchymal gene expression programs, discovering for example, novel subpopulations of cancer associated fibroblasts. These behaviors were conserved across tumors and most preclinical models, which we validated by RNA in situ hybridization, which is a high resolution ultra sensitive spatial transcriptomics technology. Our work cautions against overreliance on traditional preclinical models without recognizing their limitations and we offer a nuanced, high-resolution view of neuroblastoma pre-clinical systems for advancing therapeutic development. We have launched an open-source web resource, featuring this integrated map to aid the scientific community in further exploration of these data and hypothesis generation (available at http://pscb.stjude.org). Citation Format: Rich Chapple, Xueying Liu, Sivaraman Natarajan, Margaret I. Alexander, Yuna Kim, Anand Patel, Christy W. LaFlamme, Min Pan, William C. Wright, Hyeong-Min Lee, Yinwen Zhang, Meifen Lu, Selene C. Koo, Courtney Long, John Harper, Chandra Savage, Melissa D. Johnson, Thomas Confer, Walter J. Akers, Michael A. Dyer, Heather Sheppard, John Easton, Paul Geeleher. A novel unsupervised machine learning model applied to neuroblastoma single-cell RNA-seq data reveals a drug-induced mesenchymal-like gene expression program [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 868.

RBM39 degrader invigorates natural killer cells to eradicate neuroblastoma despite cancer cell plasticity

Novel miRNA-inducing drugs enable differentiation of retinoic acid-resistant neuroblastoma cells

Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma

Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma

Abstract 868: A novel unsupervised machine learning model applied to neuroblastoma single-cell RNA-seq data reveals a drug-induced mesenchymal-like gene expression program

Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1

Identification and characterization of chemotherapy resistant high-risk neuroblastoma persister cells

Mitochondrial uncoupler and retinoic acid synergistically induce differentiation and inhibit proliferation in neuroblastoma

In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets

Abstract 3246: Targeting Syk reprograms tumor-associated macrophages and enhances responses to immune checkpoint blockade and radiation therapy in high-risk neuroblastoma

Abstract 5344: High-throughput CRISPR-Cas9 knockout screens identify loss of miRNA1304-5p targeting the RAS/MAPK pathway as a modulator of resistance to ALK inhibitors in high-risk neuroblastoma

Reprogramming neuroblastoma by diet-enhanced polyamine depletion

Targeting SWI/SNF ATPases reduces neuroblastoma cell plasticity

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination

NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma

Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells

Abstract 947: A nanodroplet cell processing platform for identifying synergistic drug combinations for neuroblastoma treatment in TH-MYCN transgenic mice

An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs

Targeted elimination of myeloid-derived suppressor cells via regulation of the STAT pathway alleviates tumor immunosuppression in neuroblastoma